Form 4: Jazz Pharmaceuticals Director Anne O'Riordan Reports Stock Transactions

Director Anne O'Riordan reports acquisition and disposal of Jazz Pharmaceuticals plc ordinary shares related to restricted stock units.

Summary

• On August 2, 2024, Director Anne O'Riordan acquired 3,731 ordinary shares of Jazz Pharmaceuticals plc as restricted stock units at a price of $0.0.
• Following this transaction, O'Riordan beneficially owned 16,282 ordinary shares.
• On August 6, 2024, O'Riordan disposed of 1,484 ordinary shares at a price of $111.35 to satisfy tax obligations.
• After this disposal, O'Riordan beneficially owned 14,798 ordinary shares.
• The restricted stock units were granted under the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan and will vest in full on July 25, 2025, subject to continuous service and other conditions.

Sentiment

Score: 5

Explanation: The document reflects standard insider trading activity related to stock-based compensation, with no indication of unusual or concerning events. Therefore, the sentiment is neutral.

Future Outlook

The restricted stock units will vest on July 25, 2025, subject to the Reporting Person's continuous service and certain additional conditions.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities in the company's stock. It is typical for directors to receive stock-based compensation and to sell shares to cover tax obligations upon vesting.

Comparison to Industry Standards

• Stock-based compensation for directors is a common practice across the pharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock awards as part of their director compensation packages.
• The vesting schedules and terms of these awards are generally aligned with industry norms to incentivize long-term commitment and alignment with shareholder interests.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are related to standard director compensation practices.
• The disclosure provides transparency to shareholders regarding insider trading activities.

Key Dates